Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorXijing Hospital
About this trial
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
Eligibility criteria
Qualifiers
Blood prostate-specific antigen PSA>4ng/dl;
Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
The patient is willing to undergo prostate biopsy.
Disqualifiers
Previous diagnosis of prostate cancer through prostate biopsy;
History of other malignant tumors in the past two years;
According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment
Trial design
Treatments tested in this trial
- Not listed
Trial groups
1,700 Participants
are grouped into 1 trial groupSponsors and collaborators
Xijing Hospital
Lead sponsor
Shaanxi Provincial People's Hospital
Collaborator
Weinan Central Hospital
Collaborator
Shaanxi University of Chinese Medicine
Collaborator
LanZhou University
Collaborator
Qinghai University
Collaborator
Ningxia Medical University
Collaborator
Northwestern University
Collaborator
Yan'an University Affiliated Hospital
Collaborator
Air Force Military Medical University, China
Collaborator
Source ClinicalTrials.gov